The Protocol Review and Monitoring System (PRMS) oversees and ensures the prioritization, feasibility, scientific merit and progress of all clinical studies at the Cancer Therapy and Research Center (CTRC). The PRMS consists of three components that work in collaboration with one another to ensure that the right trials for the right population with the right resources open and accrue. This occurs via each of the committee's prioritization, feasibility, scientific review and progress in the selection and activation of all trials at CTRC. The PRMS evaluation process occurs prior to submission to submission to the UTHSCSA Institutional Review Board (IRB) and is required for IRB approval. The PRMS process is complementary to the IRB review and does not overlap or duplicate the responsibilities of the IRB. The IRB will not approve a protocol without the PRC's approval. Protocols are initially discussed in Clinical Disease Site Teams (CDST) teams where they receive priority scoring. Operations and Logistics Committee (O&L) where they are reviewed for feasibility, and then the Protocol Review Committee (PRC) where they receive data safety and monitoring, scientific and biostatistical reviews. After a study has opened to accrual, the PRC provides ongoing review to ensure adequate accrual and scientific progress. The PRC has the authority to close studies that have not progressed toward their intended scientific objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758431
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$77,682
Indirect Cost
$39,732
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849
Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864
Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13
Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21
Soteros, Breeanne M; Cong, Qifei; Palmer, Christian R et al. (2018) Sociability and synapse subtype-specific defects in mice lacking SRPX2, a language-associated gene. PLoS One 13:e0199399
Katti, Sachin; Her, Bin; Srivastava, Atul K et al. (2018) High affinity interactions of Pb2+ with synaptotagmin I. Metallomics 10:1211-1222
De La Chapa, Jorge J; Singha, Prajjal Kanti; Lee, Debbie R et al. (2018) Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med 47:674-682
Wang, Zhonghua; Bhattacharya, Akash; White, Tommy et al. (2018) Functionality of Redox-Active Cysteines Is Required for Restriction of Retroviral Replication by SAMHD1. Cell Rep 24:815-823

Showing the most recent 10 out of 989 publications